{"filings":[{"id":93096,"accession_number":"0001829126-26-004744","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"KALA BIO announces 1-for-50 reverse stock split effective May 8, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-50 ratio effective 4:05 p.m. ET on May 8, 2026.","Outstanding shares reduced from 929,491,578 to ~18,589,832; no fractional shares issued.","Cash paid for fractional shares based on May 7 closing price on Nasdaq Capital Market.","Ticker KALA unchanged; split-adjusted trading begins May 11, 2026; new CUSIP 483119301.","Stockholder approved reverse split at January 30, 2026 annual meeting with ratio range of 1-for-2 to 1-for-100."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104437,"accession_number":"0001829126-26-001911","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","3.02","7.01"],"status":"ready","headline":"KALA BIO launches AI infrastructure platform; licenses Researgency from Younet AI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license to Researgency platform for biotech field; initial 12-month term with renewal options.","Consideration includes up to $530k cash and issuance of 5 million shares of KALA common stock per term.","Company holds an irrevocable option to acquire Younet AI for $55 million, exercisable during the term.","Strategic pivot: KALA will deploy on-premises, data-sovereign AI for biotech clients targeting recurring revenue.","KALA will first deploy on its own MSC-S and KPI-012 data; preliminary findings expected in 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104436,"accession_number":"0001829126-26-001534","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"KALA Bio director David Lazar resigns from board effective February 16, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Lazar resigned as a member of the Board of Directors of KALA Bio on February 16, 2026.","Resignation was effective immediately and not due to any disagreement with the company.","No replacement for Lazar's board seat has been announced in this filing.","The company filed the 8-K on February 20, 2026, reflecting the departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104435,"accession_number":"0001829126-26-000995","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"KALA BIO CEO & CFO David Lazar resigns; director Avi Minkowitz appointed same day","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Lazar resigned as CEO and CFO effective Feb 2, 2026, remains on board.","Board appointed director Avi Minkowitz as new CEO and CFO effective same date.","Minkowitz previously VP at Parkit Enterprise and analyst at Leonite Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104434,"accession_number":"0001829126-26-000837","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","5.03","5.07","9.01"],"status":"ready","headline":"KALA BIO sells $4.2M Series AAA Preferred, board control shifts to AK Holdings","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Company issued 2.1M shares of Series AAA Preferred at $2/sh, raising $4.2M; each share convertible into 420 common shares (882M total potential shares).","AK Holdings appointed five directors: Avi Minkowitz, Hillel Posen, Chaim Berger, Yonatan Colman, Brendan Purdy, replacing prior board.","Stockholders approved increase in authorized common shares to 1.5B and authorized reverse stock split (1:2 to 1:100).","Six prior directors resigned (Marjan Farid, Andrew Koven, Mark Iwicki, Todd Bazemore, C. Daniel Meyers, Howard Rosen)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104433,"accession_number":"0001829126-26-000502","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"KALA BIO receives Nasdaq bid price deficiency notice; 180-day compliance period until July 20, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Letter dated Jan 20, 2026; closing bid price below $1.00 for 30 consecutive business days (Dec 3, 2025–Jan 16, 2026).","Must maintain closing bid price ≥$1.00 for at least ten consecutive business days during the compliance period to regain compliance.","If not cured by July 20, 2026, may be eligible for an additional 180-day period if other Nasdaq listing standards are met.","No immediate impact on stock listing; shares continue trading on Nasdaq subject to other requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104432,"accession_number":"0001829126-26-000110","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KALA BIO enters $15M at-market offering agreement with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate market value of shares eligible for sale under ATM prospectus supplement currently $15,000,000.","Sales commission to H.C. Wainwright set at 3.0% of gross sales price.","Company has no obligation to sell any shares under the agreement; either party may suspend offerings.","Subject to terms, Wainwright may sell shares on Nasdaq or in privately negotiated transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104431,"accession_number":"0001829126-26-000055","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"KALA BIO settles $10.6M Oxford debt for $2M; issues 4.6M shares to settle claims","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $2M to Oxford Finance, settling ~$10.6M debt obligations in full; debt overhang removed.","Issued 900,000 shares to Baker Bros. to resolve participation rights claims under prior financing.","Issued 2,200,000 shares to LifeSci Capital for unpaid financial advisory services.","Issued 1,100,000 shares to Delaware IR to settle $600,000 consulting fee; make-whole provision.","Total 4,600,000 shares issued in private, unregistered transactions (incl. 400,000 to employees)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104430,"accession_number":"0001829126-26-000023","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kala Bio pays $2M to settle $10.6M Oxford debt; loan obligations fully satisfied","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid Oxford Finance $2 million on Dec 26, 2025 under prior Settlement Agreement.","Payment settles and releases aggregate liability of approximately $10.6 million under Loan Agreement.","All obligations under Settlement Agreement and Loan Agreement are now satisfied.","Settlement resolves prior events of default by Kala Bio and subsidiary Combangio, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120727,"accession_number":"0001829126-25-010330","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["4.01","5.02"],"status":"ready","headline":"KALA Bio dismisses Deloitte, appoints HTL as auditor; 6 directors offer conditional resignations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved HTL International as independent auditor for FY 2025, replacing Deloitte & Touche.","Six directors tendered conditional resignations effective after 2025 annual meeting if proposals pass.","Resignations depend on shareholder approval of preferred stock conversion and authorized share increase.","David Lazar will remain Class II director regardless of outcome.","No disagreements with company cited for any of the director resignations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120726,"accession_number":"0001829126-25-010045","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"KALA Bio dismisses Deloitte as auditor, no new firm appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Deloitte & Touche LLP effective December 15, 2025.","No disagreements or reportable events with Deloitte in fiscal 2023 and 2024.","Deloitte's letter to SEC confirming agreement with disclosures filed as Exhibit 16.1.","New independent registered public accounting firm has not been selected yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120725,"accession_number":"0001829126-25-010037","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.08","8.01","9.01"],"status":"ready","headline":"KALA BIO CEO Lazar sells Series AAA preferred rights; consultant hired for strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting set for Jan 30, 2026; stockholder proposals and director nominations due Dec 27, 2025.","David Lazar sold his rights to purchase Series AAA Preferred Shares (up to $4.2M) to unaffiliated AK Holdings Group Inc.","Company retains consultant, a principal of AK Holdings, to advise on identifying and consummating a strategic alternative transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120724,"accession_number":"0001829126-25-009747","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"KALA BIO raises $10M in registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 900K shares and pre-funded warrants for 9.1M shares at $1.00 per share (warrants at $0.9999).","Gross proceeds of $10M; net proceeds to be used to repay indebtedness and for general corporate purposes.","Offering closed on December 5, 2025; H.C. Wainwright & Co. acted as exclusive placement agent.","Placement agent fee of 8.0% of gross proceeds plus $50K legal and $15,950 clearing expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120723,"accession_number":"0001829126-25-009432","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","5.03","5.02","9.01"],"status":"ready","headline":"KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.","Oxford loan settlement: $2M cash and 1.62M common shares reduce loan by $7M; $1M initial cash due by Jan 15, 2026 or stockholder meeting.","David Lazar appointed CEO and board chair; Mary Reumuth terminated as CFO; Gregory Perry resigns from board.","Company terminated all remaining employees in October after Oxford foreclosure; now resumes operations with limited cash from placement.","Stockholder meeting required before March 31, 2026 to approve share increase and conversion of preferred shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120722,"accession_number":"0001104659-25-110316","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"KALA BIO receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified KALA BIO on Nov 10, 2025 that MVLS was below $35M for 30 consecutive business days, violating Listing Rule 5550(b)(2).","Company also fails alternative standards: stockholders' equity <$2.5M and no net income from continuing operations in recent fiscal years.","Has until May 11, 2026 to regain compliance; if MVLS is at least $35M for 10 consecutive days, compliance is restored.","If not compliant by the deadline, stock subject to delisting; company may appeal to a Nasdaq Listing Qualifications Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120721,"accession_number":"0001104659-25-108844","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","3.02","8.01"],"status":"ready","headline":"KALA Bio enters $375k convertible loan; Oxford pauses foreclosure, company faces cash crunch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Convertible loan of up to $375k from individual investor; first $187.5k due Nov 10, remainder by Nov 12, 2025.","Loan bears 15% simple interest; lender can convert into common stock at defined prices.","Proceeds limited to negotiating further investment with lender and preparing Q3 2025 Form 10-Q.","Oxford paused asset foreclosure on Nov 3. If no additional financing, foreclosure expected to resume.","Company cannot seek alternative offers from others until Nov 17, 2025; warns of going-concern risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120720,"accession_number":"0001104659-25-100620","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.05","5.02","8.01"],"status":"ready","headline":"KALA BIO faces asset foreclosure by Oxford; CEO terminated, all staff reduced, expects delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oxford Finance forecloses on all assets, swept substantially all cash; still owed ~$9.6M.","Board terminated all employees not needed for foreclosure; CEO Todd Bazemore terminated without cause but stays as director/PEO.","Company expects no distributions to stockholders or unsecured creditors after foreclosure.","Company anticipates inability to file future SEC reports and delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120718,"accession_number":"0001104659-25-096071","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K/A","filed_at":"2025-10-02T23:59:59+00:00","items":["2.05","5.02","9.01"],"status":"ready","headline":"KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).","Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.","Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).","Company preserving cash while exploring strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120719,"accession_number":"0001104659-25-095342","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"KALA BIO receives default notice from Oxford; $29.1M debt accelerated","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Oxford Finance declared event of default under Loan Agreement citing Material Adverse Change.","All obligations immediately due and payable; total $29.1M plus default interest and expenses.","Default interest rate began accruing from date of default per Loan Agreement terms.","Company previously described Loan Agreement in its Q2 2025 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137315,"accession_number":"0001104659-25-094125","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.","Company ceases development of KPI-012 and MSC-S platform; will explore strategic options and engage with secured lender.","Board approved workforce reduction of ~19 employees (~51%); expected to complete in Q4 2025.","KPI-012 was well-tolerated with no treatment-related serious adverse events observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137314,"accession_number":"0001104659-25-091272","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Kala Bio sets 2025 annual meeting for Dec 11, adjusts stockholder proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 annual meeting set for December 11, 2025; details to be provided in proxy statement.","Rule 14a-8 stockholder proposals must be received by October 1, 2025.","Director nominations under by-laws due by September 28, 2025 (10 days after announcement).","Meeting date changed by more than 30 days from 2024 annual meeting, triggering adjusted deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137313,"accession_number":"0001104659-25-086011","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"KALA BIO appoints Todd Bazemore as permanent CEO; board election, updated compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Bazemore appointed CEO effective Aug 29, 2025, replacing his interim CEO role; also elected Class II director.","Annual base salary increased to $655,000; target annual bonus set at 60% of salary.","Severance upon qualifying termination within 24 months of change of control: 24 months salary, 200% target bonus, plus benefits.","Granted option to purchase 180,000 shares of common stock, vesting monthly over 4 years at close price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137312,"accession_number":"0001558370-25-010850","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO completes Phase 2b enrollment for KPI-012; cash runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.2M ($1.71/share) for Q2 2025 vs $9.6M ($3.16) in Q2 2024.","Cash $31.9M as of June 30; expected to fund operations into Q1 2026.","Phase 2b CHASE trial enrolled 79 patients; topline data expected end of September 2025.","R&D expenses $6.2M in Q2, up 17% YoY due to KPI-012 development costs.","Interim CEO says positive results could support a BLA submission to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137311,"accession_number":"0001104659-25-066593","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"KALA BIO completes enrollment in Phase 2b trial of KPI-012 for PCED; topline data expected Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CHASE trial randomized 79 patients across 37 sites in US and Latin America.","Two doses of KPI-012 (3 U/mL and 1 U/mL) vs vehicle, dosed QID for 56 days.","Primary endpoint: complete healing of PCED by corneal fluorescein staining photos (masked central reading).","Company expects to report topline data in Q3 2025; trial may serve as pivotal for BLA submission.","If positive, CHASE could potentially support BLA to FDA after regulatory discussion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154632,"accession_number":"0001558370-25-007664","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.","Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.","G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.","Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.","Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases."],"consensus_eps_estimate":-103.53,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154631,"accession_number":"0001104659-25-034210","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"KALA BIO enters retention agreements with three top executives; bonuses tied to CHASE trial data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retention bonuses: Bazemore $281,190, Reumuth $234,000, Brazzell $260,000.","Bonuses payable by April 18, 2025; clawback if executive resigns or is terminated for cause before earlier of Sept 30, 2025 or CHASE trial topline data announcement.","CHASE trial of KPI-012 topline data expected Q3 2025 per exhibit.","Coverage includes Interim CEO, CFO, and Head of R&D/CMO, focusing on retaining key personnel ahead of trial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173159,"accession_number":"0001558370-25-004080","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.","Raised $10.75M in December private placement with SR One, Cormorant, Woodline.","Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.","Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).","Full year 2024 net loss $38.5M ($10.15/share); no revenue."],"consensus_eps_estimate":-103.53,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173158,"accession_number":"0001104659-25-011852","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kala Bio CEO Mark Iwicki resigns; Todd Bazemore named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Iwicki resigned as CEO effective Feb 11, 2025; remains Chair of Board.","Board appointed Todd Bazemore as interim CEO and principal executive officer, effective immediately.","Bazemore had been President since Dec 2021 and COO since Nov 2017.","Prior roles include EVP/COO at Santhera and EVP/Chief Commercial Officer at Dyax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190191,"accession_number":"0001104659-24-132308","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","5.03","3.02","8.01","9.01"],"status":"ready","headline":"KALA BIO raises $10.75M in private placement; cash runway into Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10.75M from 1,340,603 common shares at $6.44 and 3,286 Series I preferred shares at $644.","Series I preferred convertible into 100 common shares per share; beneficial ownership limitation of 9.99% (up to 19.99%).","Cash resources, including proceeds, expected to fund operations into Q1 2026; net proceeds to advance KPI-012 for PCED.","Phase 2b CHASE trial enrollment over 80% complete; topline data expected Q2 2025.","Participation from new and existing investors including SR One, Cormorant, Woodline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190190,"accession_number":"0001558370-24-015168","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO Q3 net loss $9.0M; cash $49.2M; Phase 2b topline due 2Q 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.0M ($1.93/share) in Q3 2024 vs $8.7M ($3.41) in Q3 2023.","Cash $49.2M as of Sep 30, 2024; funding expected into Q4 2025; includes $3.2M from CIRM.","R&D $5.2M, G&A $4.4M; operating loss $10.0M in Q3 2024.","Phase 2b CHASE trial for PCED enrolling; topline data expected 2Q 2025; five sites in Argentina.","Exploring KPI-012 for LSCD (est. 100k patients); preclinical KPI-014 for inherited retinal diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206693,"accession_number":"0001104659-24-102775","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark S. Blumenkranz resigns from KALA BIO board immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Blumenkranz, M.D. resigned from the Board of Directors effective September 23, 2024.","He also stepped down from the Audit Committee and Nominating and Corporate Governance Committee.","Resignation was not related to any disagreement with the company's operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206692,"accession_number":"0001558370-24-010958","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO reports Q2 net loss of $9.6M, cash $54.2M; Phase 2b data due Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($3.16 per share) for Q2 2024 vs. $10.4M ($4.36 per share) a year ago.","Cash and equivalents $54.2M at June 30, 2024; with CIRM award, runway expected into Q4 2025.","Closed $12.5M private placement led by SR One; net proceeds of $12.3M.","Topline results from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025.","R&D expenses rose to $5.3M from $4.3M on higher KPI-012 development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223886,"accession_number":"0001104659-24-075388","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","5.03","3.02","8.01","9.01"],"status":"ready","headline":"KALA BIO raises $12.5M in private placement; extends cash runway into Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$12.5M from sale of 1,197,314 common shares at $5.85 and 9,393 Series H preferred shares at $585.00.","Series H preferred convertible into 100 common shares each, subject to 9.99% beneficial ownership limitation.","Cash runway extended into Q4 2025, including $9.1M remaining from CIRM award.","Proceeds to fund clinical development of KPI-012 for persistent corneal epithelial defect.","Private placement led by SR One with ADAR1 Capital and another investor; expected close June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223885,"accession_number":"0001558370-24-009093","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"KALA BIO stockholders elect three Class I directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marjan Farid, Andrew Koven, Gregory Perry elected as Class I directors for three-year terms.","Advisory vote on executive compensation approved with 764,305 votes for, 225,459 against.","Ratification of Deloitte & Touche LLP as auditor for FY2024 approved (1,825,140 for, 21,748 against).","Proposal to issue common stock upon conversion of Series E/F/G preferred stock approved (691,010 for, 49,921 against).","Three proposals to increase beneficial ownership limits on Series E/F/G preferred stock did not pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223884,"accession_number":"0001558370-24-008133","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.","Cash and equivalents $48.5M as of March 31, 2024; with CIRM award, funds operations into Q3 2025.","Q1 2024 net loss $11.8M ($4.20/share) vs $14.5M ($6.99/share) in Q1 2023; operating loss $11.9M.","R&D expenses rose to $6.4M from $4.0M year-over-year, driven by KPI-012 development.","Gross proceeds of $8.6M from March 2024 private placement partially offset cash used in ops."],"consensus_eps_estimate":-103.53,"consensus_eps_actual":-4.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243276,"accession_number":"0001558370-24-004325","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.","FY 2023 net loss $42.2M ($17.35/sh) vs $44.8M ($29.48/sh) in FY 2022.","Cash $50.9M at Dec 31, 2023; with $8.6M Mar 2024 placement, runway into Q3 2025.","R&D expenses Q4 $4.7M (up from $3.3M) driven by KPI-012 development costs.","KPI-012 Phase 2b CHASE trial for PCED enrolling; topline data targeted by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243275,"accession_number":"0001558370-24-003889","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"KALA BIO raises $8.6M in private placement of Series G convertible preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.6 million from sale of 10,901 Series G Preferred shares at $788.90 each.","Each Series G share initially convertible into 100 common shares, subject to 9.99% beneficial ownership limitation.","Closing expected on March 26, 2024; offering exempt under Section 4(a)(2) and Regulation D.","Company filed Certificate of Designations with Delaware establishing Series G Preferred Stock terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243274,"accession_number":"0001558370-24-002313","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Kala Bio targeting CHASE Phase 2b data for KPI-012 (PCED) by end of 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline safety and efficacy data from CHASE Phase 2b trial expected by year-end 2024.","KPI-012 is a human mesenchymal stem cell secretome for persistent corneal epithelial defect.","Corporate presentation posted on investors section of company website; no other material updates.","No financial guidance or operational changes disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260668,"accession_number":"0001104659-23-128542","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"KALA BIO raises ~$2.0M via private placement of Series F Convertible Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.0M from sale of 2,928 Series F Preferred shares at $683.00 per share.","Each Series F Preferred share initially convertible into 100 shares of common, subject to 9.99% beneficial ownership limitation.","Preferred stock ranks senior to common, on parity with Series E, and carries dividend rights equal to as-converted common dividends.","Closing expected on or about December 22, 2023, subject to customary conditions and exemption under Rule 506 of Regulation D.","Company agreed to restrictions on issuing senior/pari passu equity, incurring debt over $1M, or paying dividends without purchaser consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260667,"accession_number":"0001558370-23-018694","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO Q3 2023 net loss $8.7M; CHASE Phase 2b enrollment ongoing, topline data 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.7M ($3.41 per share) vs net income $29.1M in Q3 2022 due to prior year gain on sale of commercial business.","Cash and equivalents $56.1M at Sep 30, 2023; together with CIRM award funds expected to fuel operations into Q2 2025.","CHASE Phase 2b trial of KPI-012 for PCED actively enrolling; topline safety and efficacy data targeted for 2H 2024.","R&D expenses $5.6M (up $0.2M YoY); SG&A expenses $5.0M (down $4.5M YoY) after sale of commercial portfolio.","No product revenues in Q3 2023; preclinical evaluation of KPI-014 for inherited retinal degenerative diseases initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277952,"accession_number":"0001558370-23-013308","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KALA BIO Q2 net loss $10.4M; cash $59.2M; CHASE trial topline data expected Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.4M ($4.36/share) vs $28.1M ($18.92/share) in Q2 2022; operating loss $9.6M.","Cash, equivalents and short-term investments $59.2M as of June 30, 2023; CIRM $15M grant extends runway into Q2 2025.","CHASE Phase 2b trial for KPI-012 in PCED actively enrolling; topline data targeted for Q2 2024.","No product revenue after sale of commercial portfolio to Alcon in July 2022; SG&A fell to $5.0M from $22.7M.","Rebranded to KALA BIO from Kala Pharmaceuticals, reflecting focus on biologics for rare ophthalmic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277951,"accession_number":"0001558370-23-012895","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Kala Pharmaceuticals changes name to KALA BIO, Inc.; ticker KALA unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective August 2, 2023, name changed from Kala Pharmaceuticals, Inc. to KALA BIO, Inc.","Ticker symbol remains KALA on Nasdaq; trading under new name starts August 3, 2023.","Stockholder rights unaffected; CUSIP unchanged.","Board approved the name change under Delaware law; amended certificate and bylaws filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295984,"accession_number":"0001558370-23-011375","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kala shareholders approve equity plan increase, reject name change at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved A&R 2017 Equity Incentive Plan; adds 1.25M shares, extends term to June 2033.","Elected C. Daniel Myers and Howard B. Rosen as Class III directors for three-year terms.","Advisory vote on executive compensation passed (498,054 for, 57,912 against); frequency set every year.","Proposal to rename to 'Kala Bio, Inc.' did not receive required votes; 1.15M for vs 11,194 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295983,"accession_number":"0001558370-23-008683","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.","Cash and equivalents $63.6M at March 31, 2023; plus $15M CIRM grant awarded April 2023 extends runway into Q1 2025.","KPI-012 for PCED received FDA Fast Track designation; CHASE Phase 2b primary enrollment ongoing; topline data targeted Q1 2024.","Appointed Dr. Francis Mah as Chief Medical Advisor in March 2023 to support clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295982,"accession_number":"0001558370-23-007158","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kala subsidiary awarded $15M CIRM grant for KPI-012 PCED Phase 2b trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CIRM awarded Combangio a $15M grant to support KPI-012 for persistent corneal epithelial defect.","Grant funds the CHASE Phase 2b trial, product characterization, and analytical development.","Part of the award is upfront; remainder upon achieving specified milestones.","Combangio must meet a co-funding requirement; Kala committed to provide necessary funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295981,"accession_number":"0001558370-23-006578","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kala Pharmaceuticals stockholders approve option exchange and auditor ratification at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Option exchange proposal approved: 385,429 for, 57,585 against, 525,624 broker non-votes.","Ratification of Deloitte & Touche as auditor for FY2023 approved: 937,505 for, 23,974 against.","Adjournment proposal approved: 873,292 for, 94,743 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316516,"accession_number":"0001558370-23-004634","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kala Pharma reports positive safety data in CHASE Phase 2b trial of KPI-012; second cohort initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Both patients in open-label first cohort (high dose 3 U/mL QID) completed at least 1 week with no safety issues.","Second cohort is randomized, double-masked, vehicle-controlled study of ~90 patients testing two doses vs vehicle for 56 days.","Primary endpoint is complete healing of PCED measured by corneal fluorescein staining.","Topline safety and efficacy data expected in Q1 2024; positive results could support first pivotal trial for BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316515,"accession_number":"0001558370-23-002744","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kala enrolls first patient in PCED trial, closes $31M private placement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.","Closed $31.0M private placement in December 2022, extending cash runway into Q1 2025.","Completed sale of EYSUVIS and INVELTYS to Alcon in Q3 2022 to focus on rare eye diseases.","Reported Q4 and FY2022 financial results; specific figures not available in the provided excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316514,"accession_number":"0001558370-23-000362","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kala Pharma enters $40M ATM equity facility with Jefferies, prepays $10M Oxford loan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Open Market Sale Agreement with Jefferies for up to $40M in common stock at market prices; Jefferies gets up to 3% commission.","Prior $75M ATM facility fully utilized (565,974 shares sold for $75M gross proceeds); terminated Jan 10, 2023.","Company notified Oxford Finance of intent to prepay $5M by June 30, 2023 and $5M by Jan 31, 2024, reducing loan principal to ~$34M.","Prepayments include final payment fees and accrued interest; scheduled for Feb 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316513,"accession_number":"0001558370-23-000173","cik":1479419,"company_name":"KALA BIO, Inc.","ticker":"KALA","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kala Pharmaceuticals receives Nasdaq approval to transfer listing to Capital Market","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Transfer from Nasdaq Global Select to Capital Market approved, effective Jan 11, 2023.","Company met minimum stockholders' equity requirement (Rule 5550(b)(1)) and market value of publicly held shares (Rule 5550(a)(5)).","Common stock continues trading under ticker KALA on the Nasdaq Capital Market.","Listing transfer does not affect corporate governance requirements or continuous trading nature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43872002.95278969,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-10T23:59:59+00:00|316513"}